Abstract 5616: Soluble, high affinity TCRs fused to anti-CD3 redirect T cells to kill cancer cells presenting MAGE-A3 and NY-ESO antigens

Namir J. Hassan(Immunocore (United Kingdom)), Bent K. Jakobsen(Mission Therapeutics (United Kingdom)), Carl H. June(University of Pennsylvania), Nikolai M. Lissin(Immunocore (United Kingdom)), Gabriela Plesa(University of Pennsylvania), Annelise Vuidepot(Immunocore (United Kingdom)), Samantha Paston(Immunocore (United Kingdom)), Katherine J. Adams(Immunocore (United Kingdom)), Daniel Williams(Immunocore (United Kingdom)), Michael Kalos(Pillar College), Rebecca Dennis(Immunocore (United Kingdom)), Deborah H. Sutton(Immunocore (United Kingdom)), Yvonne McGrath(Immunocore (United Kingdom)), Nick Pumphrey(Immunocore (United Kingdom)), Emma Gostick(University Hospital of Wales), Peter Molloy(AXON Neuroscience (Slovakia)), Giovanna Bossi(Immunocore (United Kingdom)), Andrew M. Johnson(Orthox (United Kingdom)), Frayne Bianchi(Immunocore (United Kingdom)), Naomi E. Harwood(Immunocore (United Kingdom)), Brian Cameron(Immunocore (United Kingdom)), Nathaniel Liddy(Immunocore (United Kingdom)), Jessie Gavarret(Immunocore (United Kingdom)), Yi Li(Immunocore (United Kingdom)), David A. Price(University Hospital of Wales), Tara Mahon(Immunocore (United Kingdom)), Emma Baston(Immunocore (United Kingdom)), Anna Lissina(At Bristol), Malkit Sami(Immunocore (United Kingdom)), Jane Harper(Immunocore (United Kingdom)), Rebecca Ashfield(Immunocore (United Kingdom)), Penio Todorov(Immunocore (United Kingdom)), Andrew K. Sewell(Cardiff University)
Cancer Research
April 1, 2010
Cited by 1


Related Papers